JP2001509157A - 時間特異的放出制御型投与製剤及びその製法 - Google Patents
時間特異的放出制御型投与製剤及びその製法Info
- Publication number
- JP2001509157A JP2001509157A JP53177098A JP53177098A JP2001509157A JP 2001509157 A JP2001509157 A JP 2001509157A JP 53177098 A JP53177098 A JP 53177098A JP 53177098 A JP53177098 A JP 53177098A JP 2001509157 A JP2001509157 A JP 2001509157A
- Authority
- JP
- Japan
- Prior art keywords
- core
- coating layer
- swellable polymer
- polymer coating
- pharmaceutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.医薬活性をもつ物質の治療効果を必要とする患者に医薬活性をもつ物質を 時間特異的に配送する方法であって、(a)前記医薬活性をもつ物質を含むコア と、(b)前記コアを実質的に取り囲む膨潤性ポリマーコーティング層であって 、前記コアからの前記医薬活性をもつ物質の放出をその膨潤性ポリマーコーティ ング層の厚さに依存する所定の期間遅らせる膨潤性ポリマーコーティング層とを 含み、前記膨潤性ポリマーコーティング層が、(I)前記コアをバインダー溶液 で濡らし、(ii)コアを粉末状ポリマー粒子でコーティングすることを、望まし い厚さの膨潤性ポリマーコーティング層を有する時間特異的投与製剤を製造する のに十分な回数交互に繰り返すことにより提供されるものである医薬製剤を、前 記患者に投与することを含む方法。 2.前記医薬製剤が経口投与される請求項1記載の方法。 3.前記医薬活性をもつ物質が、ステロイド、キサンチン、β−2−アゴニス ト気管支拡張薬、抗炎症剤、鎮痛剤、カルシウム拮抗物質、アンギオテンシン変 換酵素阻害剤、β−ブロッカー、中心活性α−アゴニスト、α−1−アンタゴニ スト、抗コリン作動剤/抗痙攣剤、バソプレシン類似物、抗不整脈剤、抗パーキ ンソン剤、抗アンギナ剤及び抗高血圧症剤、抗凝血剤、抗血小板剤、鎮静剤、杭 不安剤、ペプチド剤、生体高分子剤、抗腫瘍剤、緩下剤、止瀉剤、抗微生物剤、 抗菌剤、ワクチン及び核酸からなる群から選ばれる請求項1記載の方法。 4.前記膨潤性ポリマーコーティング層が、ヒドロキシプロピルメチルセルロ ース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ポリビニ ルピロリドン、ポリビニルアルコール、 アクリル酸ポリマー、メタクリル酸コポリマー、エチルアクリレートーメチルメ タクリレートコポリマー及びこれらの混合物からなる群から選ばれる粉末状ポリ マー粒子を含む請求項1記載の方法。 5.前記バインダー溶液が、ポリビニルピロリドン、ヒドロキシプロピルメチ ルセルロース、ポリビニルアルコール、ヒドロキシエチルセルロース、メタクリ ル酸コポリマー、エチルアクリレート−メチルメタクリレートコポリマー、グア ーゴム、アラビアゴム、キサンタンゴム、ゼラチン、ペクチン及びこれらの混合 物からなる群から選ばれる請求項1記載の方法。 6.前記膨潤性ポリマーコーティング層が高分子ヒドロキシプロピルメチルセ ルロース粒子を含む請求項1記載の方法。 7.前記バインダー溶液がポリビニルピロリドンである請求項1記載の方法。 8.前記膨潤性ポリマーコーティング層の厚さが50μm以上である請求項1 記載の方法。 9.前記膨潤性ポリマーコーティング層の厚さが、約20:1〜約1:5のコ ア:コーティング層比を達成するのに十分なものである請求項1記載の方法。 10.前記膨潤性ポリマーコーティング層の厚さが、約5:1〜約1:3のコ ア:コーティング層比を達成するのに十分なものである請求項1記載の方法。 11.医薬活性をもつ物質の治療効果を必要とする患者に医薬活性をもつ物質 を時間特異的に配送する方法であって、(a)前記医薬活性をもつ物質を含むコ アと、(b)前記コアを実質的に取り囲む膨潤性ポリマーコーティング層であっ て、前記コアからの前記医薬活性をもつ物質の放出をその膨潤性ポリマーコーテ ィング層の厚さに依存する所定の期間遅らせる膨潤性ポリマーコーティング層と を含み、前記膨潤性ポリマーコーティング層が粉末状ポリマー粒子から形成され るものである医薬製剤を前記患者に投与することを含む方法。 12.医薬活性をもつ物質を時間特異的に配送するための時間特異的投与製剤 の製造方法であって、医薬活性をもつ物質を含むコアを、前記コアからの前記医 薬活性をもつ物質の放出をその膨潤性ポリマーコーティング層の厚さに依存する 所定の期間遅らせる膨潤性ポリマーコーティング層でコーティングすることを含 み、前記コアを前記膨潤性ポリマーコーティング層でコーティングする前記ステ ップが(I)前記コアをバインダー溶液で濡らし、(ii)コアを粉末状ポリマー 粒子でコーティングすることを、望ましい厚さの膨潤性ポリマーコーティング層 を有する時間特異的投与製剤を製造するのに十分な回数交互に繰り返すことを含 む方法。 13.前記医薬活性をもつ物質が、ステロイド、キサンチン、β−2−アゴニ スト気管支拡張薬、抗炎症剤、鎮痛剤、カルシウム拮抗物質、アンギオテンシン 変換酵素阻害剤、β−ブロッカー、中心活性α−アゴニスト、α−1−アンタゴ ニスト、抗コリン作動剤/抗痙攣剤、バソプレシン類似物、抗不整脈剤、抗パー キンソン剤、抗アンギナ剤及び抗高血圧症剤、抗凝血剤、抗血小板剤、鎮静剤、 抗不安剤、ペプチド剤、生体高分子剤、抗腫瘍剤、緩下剤、止瀉剤、抗微生物剤 、抗菌剤、ワクチン及び核酸からなる群から選ばれる請求項12記載の方法。 14.前記膨潤性ポリマーコーティング層が、ヒドロキシプロピルメチルセル ロース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ポリビ ニルピロリドン、ポリビニルアルコール、アクリル酸ポリマー、メタクリル酸コ ポリマー、エチルアクリレート−メチルメタクリレートコポリマー及びこれらの 混合物からな る群から選ばれる粉末状ポリマー粒子を含む請求項12記載の方法。 15.前記バインダー溶液が、ポリビニルピロリドン、ヒドロキシプロピルメ チルセルロース、ポリビニルアルコール、ヒドロキシエチルセルロース、メタク リル酸コポリマー、エチルアクリレート−メチルメタクリレートコポリマー、グ アーゴム、アラビアゴム、キサンタンゴム、ゼラチン、ペクチン及びこれらの混 合物からなる群から選ばれる請求項12記載の方法。 16.前記コアを前記膨潤性ポリマーコーティング層でコーティングするステ ップが、厚さが50μm以上の膨潤剤ポリマーコーティング層で前記コアをコー ティングすることを含む請求項12記載の方法。 17.前記コアを前記膨潤性ポリマーコーティング層でコーティングするステ ップが、約20:1〜約1:5のコア:コーティング層比となるように前記コア を膨潤性ポリマーコーティング層でコーティングすることを含む請求項12記載 の方法。 18.医薬活性をもつ物質の治療効果を必要とする患者に医薬活性をもつ物質 を時間特異的に配送する方法であって、(a)液状の前記医薬活性をもつ物質を 含むカプセルを含むコアと、(b)前記コアを実質的に取り囲む膨潤性ポリマー コーティング層であって、前記コアからの前記医薬活性をもつ物質の放出をその 膨潤性ポリマーコーティング層の厚さに依存する所定の期間遅らせる膨潤性ポリ マーコーティング層とを含み、前記膨潤性ポリマーコーティング層が(I)前記 コアをバインダー溶液で濡らし、(ii)前記コアを粉末状ポリマー粒子でコーテ ィングすることを、望ましい厚さの膨潤性ポリマーコーティング層を有する時間 特異的投与製剤を製造するのに十分な回数交互に繰り返すことにより提供される ものである医 薬製剤を、前記患者に投与することを含む方法。 19.前記医薬製剤が経口投与される請求項18記載の方法。 20.液状の前記医薬活性をもつ物質が、溶液、リポソーム分散体、水中油滴 型エマルション、マイクロエマルション、マイクロエマルション及びリポソーム の前駆体、マイクロパーティクルの分散体、ナノパーティクルの分散体、固形脂 質ナノパーティクルの分散体並びに懸濁液からなる群から選ばれる請求項18記 載の方法。 21.前記医薬活性をもつ物質が、ステロイド、キサンチン、β−2−アゴニ スト気管支拡張薬、抗炎症剤、鎮痛剤、カルシウム拮抗物質、アンギオテンシン 変換酵素阻害剤、β−ブロッカー、中心活性α−アゴニスト、α−1−アンタゴ ニスト、抗コリン作動剤/抗痙攣剤、バソプレシン類似物、抗不整脈剤、抗パー キンソン剤、抗アンギナ剤及び抗高血圧症剤、抗凝血剤、抗血小板剤、鎮静剤、 抗不安剤、ペプチド剤、生体高分子剤、抗腫瘍剤、緩下剤、止瀉剤、抗微生物剤 、抗菌剤、ワクチン及び核酸からなる群から選ばれる請求項18記載の方法。 22.前記膨潤性ポリマーコーティング層が、ヒドロキシプロピルメチルセル ロース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ポリビ ニルピロリドン、ポリビニルアルコール、アクリル酸ポリマー、メタクリル酸コ ポリマー、エチルアクリレート−メチルメタクリレートコポリマー及びこれらの 混合物からなる群から選ばれる粉末状ポリマー粒子を含む請求項18記載の方法 。 23.前記バインダー溶液が、ポリビニルピロリドン、ヒドロキシプロピルメ チルセルロース、ポリビニルアルコール、ヒドロキシエチルセルロース、メタク リル酸コポリマー、エチルアクリレート−メチルメタクリレートコポリマー、グ アーゴム、アラビアゴム、 キサンタンゴム、ゼラチン、ペクチン及びこれらの混合物からなる群から選ばれ る請求項18記載の方法。 24.前記膨潤性ポリマーコーティング層が高分子ヒドロキシプロピルメチル セルロース粒子を含む請求項18記載の方法。 25.前記バインダー溶液がポリビニルピロリドンである請求項18記載の方 法。 26.前記膨潤性ポリマーコーティング層の厚さが50μm以上である請求項 18記載の方法。 27.前記膨潤性ポリマーコーティング層の厚さが、約20:1〜約1:5の コア:コーティング層比となるのに十分に厚い請求項18記載の方法。 28.前記膨潤性ポリマーコーティング層の厚さが、約5:1〜約1:3のコ ア:コーティング層比となるのに十分に厚い請求項18記載の方法。 29.医薬活性をもつ物質の治療効果を必要とする患者に医薬活性をもつ物質 を時間特異的に配送する方法であって、(a)液状の前記医薬活性をもつ物質を 含むカプセルを含むコアと、(b)前記コアを実質的に取り囲む膨潤性ポリマー コーティング層であって、前記コアからの前記医薬活性をもつ物質の放出をその 膨潤性ポリマーコーティング層の厚さに依存する所定の期間遅らせる膨潤性ポリ マーコーティング層とを含み、前記膨潤性ポリマーコーティング層が粉末状ポリ マー粒子から形成されたものである医薬製剤を、前記患者に投与することを含む 方法。 30.医薬活性をもつ物質を時間特異的に配送するための時間特異的投与製剤 の製造方法であって、液状の医薬活性をもつ物質を含むカプセルを含むコアを、 前記コアからの前記医薬活性をもつ物質の放出をその膨潤性ポリマーコーティン グ層の厚さに依存する所定 の期間遅らせる膨潤性ポリマーコーティング層でコーティングすることを含み、 前記コアを前記膨潤性ポリマーコーティング層でコーティングするステップが( I)前記コアをバインダー溶液で濡らし、(ii)前記コアを粉末状ポリマー粒子 でコーティングすることを、望ましい厚さの膨潤性ポリマーコーティング層を有 する時間特異的投与製剤を製造するのに十分な回数交互に繰り返すことを含む方 法。 31.(1)溶液、リポソーム分散体、水中油滴型エマルション、マイクロエ マルション、マイクロエマルション及びリポソームの前駆体、マイクロパーティ クルの分散体、ナノパーティクルの分散体、固形脂質ナノパーティクルの分散体 並びに懸濁液からなる群から選ばれる液状の前記医薬活性をもつ物質を提供する ステップと、(2)前記コアをコーティングするステップの前にカプセルに前記 液状の医薬活性をもつ物質を封入するステップとをさらに含む請求項30記載の 方法。 32.前記医薬活性をもつ物質が、ステロイド、キサンチン、β−2−アゴニ スト気管支拡張薬、抗炎症剤、鎮痛剤、カルシウム拮抗物質、アンギオテンシン 変換酵素阻害剤、β−ブロッカー、中心活性α−アゴニスト、α−1−アンタゴ ニスト、抗コリン作動剤/抗痙攣剤、バソプレシン類似物、抗不整脈剤、抗パー キンソン剤、抗アンギナ剤及び抗高血圧症剤、抗凝血剤、抗血小板剤、鎮静剤、 抗不安剤、ペプチド剤、生体高分子剤、抗腫瘍剤、緩下剤、止瀉剤、抗微生物剤 、抗菌剤、ワクチン及び核酸からなる群から選ばれる請求項30記載の方法。 33.前記膨潤性ポリマーコーティング層が、ヒドロキシプロピルメチルセル ロース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ポリビ ニルピロリドン、ポリビニルアルコール 、アクリル酸ポリマー、メタクリル酸コポリマー、エチルアクリレート−メチル メタクリレートコポリマー及びこれらの混合物からなる群から選ばれる粉末状ポ リマー粒子を含む請求項30記載の方法。 34.前記バインダー溶液が、ポリビニルピロリドン、ヒドロキシプロピルメ チルセルロース、ポリビニルアルコール、ヒドロキシエチルセルロース、メタク リル酸コポリマー、エチルアクリレート−メチルメタクリレートコポリマー、グ アーゴム、アラビアゴム、キサンタンゴム、ゼラチン、ペクチン及びこれらの混 合物からなる群から選ばれる請求項30記載の方法。 35.前記コアを前記膨潤性ポリマーコーティング層でコーティングするステ ップが、前記コアを、厚さが50μm以上の膨潤性ポリマーコーティング層でコ ーティングすることを含む請求項30記載の方法。 36.前記コアを前記膨潤性ポリマーコーティング層でコーティングするステ ップが、コア:コーティング層比が約20:1〜約1:5となるように前記コア を膨潤性ポリマーコーティング層でコーティングすることを含む請求項30記載 の方法。 37.医薬活性をもつ物質を時間特異的に配送するための医薬製剤であって、 (a)液状の前記医薬活性をもつ物質を含むカプセルを含むコア、並びに (b)前記コアを実質的に取り囲み、前記コアからの前記医薬活性をもつ物質 の放出をその膨潤性ポリマーコーティング層の厚さに依存する所定の期間遅らせ る膨潤性ポリマーコーティング層であって、(I)前記コアをバインダー溶液で 濡らし、(ii)前記コアを粉末状ポリマー粒子でコーティングすることを、望ま しい厚さの膨 潤性ポリマーコーティング層を有する時間特異的投与製剤を製造するのに十分な 回数交互に繰り返すことにより提供されるもの、 を含む医薬製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/790,530 US5891474A (en) | 1997-01-29 | 1997-01-29 | Time-specific controlled release dosage formulations and method of preparing same |
US08/790,530 | 1997-01-29 | ||
PCT/IB1997/001646 WO1998032426A1 (en) | 1997-01-29 | 1997-12-16 | Time-specific controlled release dosage formulations and method of preparing same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001509157A true JP2001509157A (ja) | 2001-07-10 |
JP4053604B2 JP4053604B2 (ja) | 2008-02-27 |
Family
ID=25150977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53177098A Expired - Fee Related JP4053604B2 (ja) | 1997-01-29 | 1997-12-16 | 時間特異的放出制御型投与製剤及びその製法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US5891474A (ja) |
EP (1) | EP0954293B1 (ja) |
JP (1) | JP4053604B2 (ja) |
AU (1) | AU5675598A (ja) |
DE (1) | DE69731847T2 (ja) |
ES (1) | ES2232886T3 (ja) |
PT (1) | PT954293E (ja) |
WO (1) | WO1998032426A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007505921A (ja) * | 2003-09-19 | 2007-03-15 | ペンウェスト ファーマシューティカルズ カンパニー | 遅延放出剤形 |
Families Citing this family (361)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
IN186245B (ja) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
US6296871B1 (en) * | 1998-04-12 | 2001-10-02 | Ranbaxy Laboratories Limited | Stable solid pharmaceutical compositions containing enalapril maleate |
US6602521B1 (en) * | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
US20010055613A1 (en) * | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
DE19856432A1 (de) * | 1998-12-08 | 2000-06-15 | Basf Ag | Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen |
ES2267491T3 (es) * | 1999-01-21 | 2007-03-16 | Circ Pharma Research And Development Limited | Formulacion de bisoprolol de multiples particulas. |
US6733789B1 (en) | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
ATE251449T1 (de) * | 1999-06-14 | 2003-10-15 | Cosmo Spa | Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe |
US8895064B2 (en) | 1999-06-14 | 2014-11-25 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
US20030225124A1 (en) * | 1999-08-31 | 2003-12-04 | Spiridon Spireas | Stable formulations of ACE inhibitors, and methods for preparation thereof |
US20030124225A1 (en) * | 1999-11-01 | 2003-07-03 | Paul West | Encapsulated alcoholic beverage |
US20040185099A1 (en) * | 2000-01-20 | 2004-09-23 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
AU767812B2 (en) | 2000-02-04 | 2003-11-27 | Depomed, Inc. | Shell-and-core dosage form approaching zero-order drug release |
AU2001275043A1 (en) | 2000-05-31 | 2001-12-11 | Drugtech Corporation | Mineral supplement |
DE10031043A1 (de) * | 2000-06-26 | 2002-02-14 | Bayer Ag | Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung |
US6491950B1 (en) * | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
DE20100529U1 (de) * | 2001-01-11 | 2001-05-10 | Synthon Bv | Pharmazeutische Tablette umfassend Paroxetinmesylat |
SE0100824D0 (sv) * | 2001-03-09 | 2001-03-09 | Astrazeneca Ab | Method III to obtain microparticles |
IL157634A0 (en) * | 2001-03-13 | 2004-03-28 | Penwest Pharmaceuticals Co | Chronotherapeutic dosage forms containing glucocorticosteroid |
US20030072731A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing starch or dextrin |
AU4061702A (en) * | 2001-05-15 | 2003-04-03 | Mcneil-Ppc, Inc. | Dip coating compositions containing starch or dextrin |
US20030070584A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
ATE376832T1 (de) * | 2001-07-06 | 2007-11-15 | Penwest Pharmaceuticals Co | Verzögert freisetzende formulierungen von oxymorphon |
DE60219478T2 (de) * | 2001-07-06 | 2008-01-03 | Endo Pharmaceuticals Inc. | Orale gabe von 6-hydroxy-oxymorphon als analgetikum |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
CA2459976A1 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
US8309118B2 (en) * | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
US9358214B2 (en) * | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US6500454B1 (en) * | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20030118652A1 (en) * | 2001-11-15 | 2003-06-26 | John Kelly | Methods and compositions for use of (S)-bisoprolol |
US20030091633A1 (en) * | 2001-11-15 | 2003-05-15 | John Kelly | Methods and compositions for use of (S)-bisoprolol |
US20050025824A1 (en) * | 2001-12-14 | 2005-02-03 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
US6663888B2 (en) * | 2001-12-14 | 2003-12-16 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
IL162496A0 (en) * | 2001-12-14 | 2005-11-20 | Jagotec Ag | Pharmaceutical compositions containing cyclosporin |
EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
SI1476138T1 (sl) | 2002-02-21 | 2012-07-31 | Valeant Internat Barbados Srl | Formulacije s prirejenim sproščanjem vsaj ene oblike tramadola |
US7429619B2 (en) * | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
BR0313207A (pt) * | 2002-08-02 | 2005-06-28 | Ranbaxy Lab Ltd | Comprimidos de fosinopril de sódio estável ao armazenamento, processo para sua preparação e método para tratar a hipertensão |
US20040029959A1 (en) * | 2002-08-08 | 2004-02-12 | John Devane | Isosorbide mononitrate compositions and methods of their use |
EP1545468A4 (en) * | 2002-09-20 | 2007-06-20 | Alpharma Inc | SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE |
US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
US20040091544A1 (en) * | 2002-11-08 | 2004-05-13 | Ruff Michael D. | Coated dibasic calcium phosphate |
US9107804B2 (en) | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
US8367111B2 (en) * | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
EP1608347B1 (en) * | 2003-03-28 | 2014-08-13 | Sigmoid Pharma Limited | Solid oral dosage form containing seamless microcapsules |
US7314640B2 (en) * | 2003-07-11 | 2008-01-01 | Mongkol Sriwongjanya | Formulation and process for drug loaded cores |
JP2007519608A (ja) * | 2003-09-19 | 2007-07-19 | ペンウェスト ファーマシューティカルズ カンパニー | 時間治療用剤形 |
US7498309B2 (en) * | 2003-11-29 | 2009-03-03 | Sangstat Medical Corporation | Pharmaceutical compositions for bioactive peptide agents |
US20060003001A1 (en) * | 2004-02-11 | 2006-01-05 | John Devane | Chronotherapeutic compositions and methods of their use |
US20070224269A1 (en) * | 2004-06-10 | 2007-09-27 | Rubino Orapin P | Controlled Release Pharmaceutical Formulation |
US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
US8747895B2 (en) * | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US20080113031A1 (en) * | 2004-09-27 | 2008-05-15 | Joey Moodley | Minicapsule Formulations |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
NZ709754A (en) | 2004-10-21 | 2017-02-24 | Adare Pharmaceuticals Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
KR100679111B1 (ko) | 2004-11-20 | 2007-02-07 | 대우약품공업주식회사 | 독사조신을 포함하는 서방성 정제 |
JP5242375B2 (ja) | 2005-04-01 | 2013-07-24 | ザ レゲントス オブ ザ ユニバーシティ オブ カリフォルニア | ホスホノ−ペント−2−エン−1−イルヌクレオシド及び類似体 |
US20090156545A1 (en) * | 2005-04-01 | 2009-06-18 | Hostetler Karl Y | Substituted Phosphate Esters of Nucleoside Phosphonates |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
AU2006275476A1 (en) * | 2005-08-01 | 2007-02-08 | Alpharma Inc. | Alcohol resistant pharmaceutical formulations |
EP1754471A1 (de) * | 2005-08-18 | 2007-02-21 | ORAMON-Arzneimittel GmbH & Co. KG | Verwendung einer quellbaren Zwischenschicht zur Steuerung des Freisetzungsprofils einer festen Arzneimittelformulierung zur peroralen Anwendung und diese enthaltende Arzneimittelformulierung |
RU2457854C2 (ru) * | 2005-12-30 | 2012-08-10 | Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед | Длительное высвобождение нейрегулина для улучшения сердечной функции |
FR2897267A1 (fr) * | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
KR20080104149A (ko) * | 2006-03-13 | 2008-12-01 | 엔싸이시브 파마슈티칼즈 인코퍼레이티드 | 확장기 심장 부전의 치료를 위한 방법 및 조성물 |
CA2644784A1 (en) * | 2006-03-13 | 2007-09-20 | Jinling Chen | Formulations of sitaxsentan sodium |
AU2007225088B2 (en) | 2006-03-13 | 2012-09-13 | Kyorin Pharmaceutical Co., Ltd | Aminoquinolones as GSK-3 inhibitors |
JP5257070B2 (ja) | 2006-06-13 | 2013-08-07 | 日本新薬株式会社 | 被覆錠剤 |
US20080026061A1 (en) * | 2006-06-22 | 2008-01-31 | Reichwein John F | Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide |
NZ575907A (en) | 2006-09-21 | 2011-03-31 | Kyorin Seiyaku Kk | 5-substituted benzoxazines |
JP2010507585A (ja) | 2006-10-19 | 2010-03-11 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換インドール |
WO2008052136A2 (en) | 2006-10-25 | 2008-05-02 | Proteus Biomedical, Inc. | Controlled activation ingestible identifier |
US20100137421A1 (en) * | 2006-11-08 | 2010-06-03 | Emmanuel Theodorakis | Small molecule therapeutics, synthesis of analogues and derivatives and methods of use |
JP2010510987A (ja) | 2006-11-27 | 2010-04-08 | ハー・ルンドベック・アクチエゼルスカベット | ヘテロアリールアミド誘導体 |
WO2008079371A1 (en) * | 2006-12-22 | 2008-07-03 | Encysive Pharmaceuticals, Inc. | Modulators of c3a receptor and methods of use thereof |
WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
BRPI0808089A2 (pt) | 2007-02-28 | 2014-07-15 | Conatus Pharmaceuticals Inc | Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c. |
WO2008109018A1 (en) * | 2007-03-02 | 2008-09-12 | Meda Pharmaceuticals Inc. | Compositions comprising carisoprodol and methods of use thereof |
US20080234257A1 (en) | 2007-03-15 | 2008-09-25 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
CN103120653B (zh) | 2007-04-04 | 2015-09-30 | 希格默伊德药业有限公司 | 一种口服药物组合物 |
JP2010527285A (ja) * | 2007-04-26 | 2010-08-12 | シグモイド・ファーマ・リミテッド | 複数のミニカプセルの製造 |
US20100239665A1 (en) * | 2007-05-01 | 2010-09-23 | Ivan Coulter | Pharmaceutical nimodipine compositions |
US7892776B2 (en) | 2007-05-04 | 2011-02-22 | The Regents Of The University Of California | Screening assay to identify modulators of protein kinase A |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
BRPI0814542A2 (pt) * | 2007-07-12 | 2014-09-30 | Tragara Pharmaceuticals Inc | Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores |
CA2699151A1 (en) * | 2007-09-11 | 2009-03-19 | Activx Biosciences, Inc. | Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors |
CA2699152C (en) | 2007-09-12 | 2015-11-24 | Activx Biosciences, Inc. | Spirocyclic aminoquinolones as gsk-3 inhibitors |
CA2704209C (en) * | 2007-10-31 | 2017-02-28 | Mcneil-Ppc, Inc. | Orally disintegrative dosage form |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
DK2268623T3 (en) * | 2008-03-17 | 2015-06-29 | Ambit Biosciences Corp | QUINAZOLINE DERIVATIVES AS RAF CHINESE MODULATORS AND PROCEDURES FOR USE THEREOF |
WO2009139880A1 (en) * | 2008-05-13 | 2009-11-19 | Celgene Corporation | Thioxoisoindoline compounds and compositions and methods of using the same |
MX2010012514A (es) * | 2008-05-20 | 2011-05-30 | Cerenis Therapeutics S A | Niacina y un medicamento nsaid para tratamiento combinado. |
JP2011526893A (ja) | 2008-07-02 | 2011-10-20 | イデニク プハルマセウティカルス,インコーポレイテッド | ウイルス感染の治療のための化合物、及び医薬組成物 |
US20110256305A1 (en) * | 2008-12-23 | 2011-10-20 | Harmonium International Inc. | Turbine Coating Apparatus And Spray Gun Assembly Therefor |
CA2748389A1 (en) | 2008-12-31 | 2010-07-08 | Scynexis, Inc. | Derivatives of cyclosporin a |
WO2010088450A2 (en) | 2009-01-30 | 2010-08-05 | Celladon Corporation | Methods for treating diseases associated with the modulation of serca |
US8568793B2 (en) | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
SI2401267T1 (sl) | 2009-02-27 | 2014-05-30 | Ambit Biosciences Corporation | Derivati kinazolina, ki modulirajo JAK-kinazo, in njihova uporaba v postopkih |
WO2010101967A2 (en) | 2009-03-04 | 2010-09-10 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole hcv polymerase inhibitors |
MX2011009414A (es) * | 2009-03-11 | 2011-10-19 | Kyorin Seiyaku Kk | 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3. |
MX2011009413A (es) | 2009-03-11 | 2011-10-21 | Ambit Biosciences Corp | Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer. |
WO2010110686A1 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy |
US8461158B2 (en) | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
NZ595838A (en) | 2009-04-22 | 2014-03-28 | Axikin Pharmaceuticals Inc | Arylsulfonamide ccr3 antagonists |
SG10201505313RA (en) | 2009-04-22 | 2015-08-28 | Axikin Pharmaceuticals Inc | 2,5-Disubstituted Arylsulfonamide CCR3 Antagonists |
CA2758985A1 (en) | 2009-04-22 | 2010-10-28 | Axikin Pharmaceuticals, Inc. | 2,5-disubstituted arylsulfonamide ccr3 antagonists |
EP3300723A1 (en) | 2009-05-18 | 2018-04-04 | Sigmoid Pharma Limited | Composition comprising oil drops |
WO2011003870A2 (en) | 2009-07-06 | 2011-01-13 | Creabilis S.A. | Mini-pegylated corticosteroids, compositions including same, and methods of making and using same |
TW201105662A (en) | 2009-07-07 | 2011-02-16 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
CA2767168C (en) | 2009-07-08 | 2019-04-09 | Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals | Sodium thiosulfate-containing pharmaceutical compositions |
WO2011009961A1 (en) | 2009-07-24 | 2011-01-27 | Virologik Gmbh | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
JP2013501068A (ja) | 2009-08-05 | 2013-01-10 | アイディニックス ファーマシューティカルズ インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
JP5911799B2 (ja) | 2009-08-12 | 2016-04-27 | シグモイド・ファーマ・リミテッドSigmoid Pharma Limited | ポリマーマトリックスおよび油相を含んで成る免疫調節組成物 |
EP2467137A1 (en) | 2009-08-19 | 2012-06-27 | Ambit Biosciences Corporation | Biaryl compounds and methods of use thereof |
US9610224B2 (en) | 2009-09-24 | 2017-04-04 | Johnson & Johnson Consumer Inc. | Manufacture of tablet in a die utilizing powder blend containing water-containing material |
US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
US8858210B2 (en) | 2009-09-24 | 2014-10-14 | Mcneil-Ppc, Inc. | Manufacture of variable density dosage forms utilizing radiofrequency energy |
WO2011056566A2 (en) | 2009-10-26 | 2011-05-12 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
WO2011056764A1 (en) | 2009-11-05 | 2011-05-12 | Ambit Biosciences Corp. | Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles |
WO2011064769A1 (en) | 2009-11-24 | 2011-06-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and pharmaceutical compositions for the treatment of hot flashes |
US20110301235A1 (en) | 2009-12-02 | 2011-12-08 | Alquest Therapeutics, Inc. | Organoselenium compounds and uses thereof |
MX2012006240A (es) | 2009-12-02 | 2012-10-03 | Aptalis Pharma Ltd | Microcapsulas de fexofenadina y composiciones que contienen las mismas. |
CN102552919B (zh) * | 2010-12-15 | 2018-03-27 | 上海安博生物医药股份有限公司 | 一种给药组合物及其制备和使用方法 |
JP2013514976A (ja) * | 2009-12-16 | 2013-05-02 | ノッド ファーマシューティカルズ, インコーポレイテッド | 経口薬物送達のための組成物および方法 |
NZ600608A (en) | 2009-12-18 | 2015-01-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
EP2515654A4 (en) * | 2009-12-23 | 2013-04-24 | Map Pharmaceuticals Inc | NEW ERGOLINANALOGA |
KR20120125610A (ko) | 2009-12-30 | 2012-11-16 | 싸이넥시스, 인크. | 시클로스포린 유사체 |
WO2011089167A1 (en) | 2010-01-19 | 2011-07-28 | Virologik Gmbh | Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
EP2531197B1 (en) | 2010-02-05 | 2017-05-17 | Tragara Pharmaceuticals, Inc. | Solid state forms of macrocyclic kinase inhibitors |
EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
HUE025699T2 (en) | 2010-03-02 | 2016-04-28 | Axikin Pharmaceuticals Inc | Isotopically enriched arylsulfonamide derivatives as CCR3 antagonists |
WO2011112689A2 (en) | 2010-03-11 | 2011-09-15 | Ambit Biosciences Corp. | Saltz of an indazolylpyrrolotriazine |
CN102892754A (zh) | 2010-03-17 | 2013-01-23 | 埃克希金医药品有限公司 | 芳基磺酰胺ccr3拮抗剂 |
WO2011150198A1 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl urea compounds and methods of use thereof |
WO2011150201A2 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl amide compounds and methods of use thereof |
CA2801001A1 (en) | 2010-06-01 | 2011-12-08 | Biotheryx, Inc. | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases |
WO2011153199A1 (en) | 2010-06-01 | 2011-12-08 | Biotheryx, Inc. | Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone |
AU2011265047B2 (en) | 2010-06-07 | 2014-10-23 | Novomedix, Llc | Furanyl compounds and the use thereof |
MX347927B (es) | 2010-07-19 | 2017-05-19 | Summa Health System | Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb. |
WO2012030918A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Adenosine a3 receptor modulating compounds and methods of use thereof |
EP2663553B1 (en) | 2010-09-01 | 2015-08-26 | Ambit Biosciences Corporation | Quinoline and isoquinoline derivatives for use as jak modulators |
EP2611794A1 (en) | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | 4-azolylaminoquinazoline derivatives and methods of use thereof |
CA2809993A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
WO2012030924A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Azolopyridine and azolopyrimidine compounds and methods of use thereof |
US20130225615A1 (en) | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
MX2013002383A (es) | 2010-09-01 | 2013-07-05 | Ambit Biosciences Corp | Sales bromhidrato de una pirazolilaminoquinazolina. |
US20130317045A1 (en) | 2010-09-01 | 2013-11-28 | Ambit Biosciences Corporation | Thienopyridine and thienopyrimidine compounds and methods of use thereof |
WO2012030948A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Quinazoline compounds and methods of use thereof |
US20130225578A1 (en) | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 7-cyclylquinazoline derivatives and methods of use thereof |
WO2012044641A1 (en) | 2010-09-29 | 2012-04-05 | Pathway Therapeutics Inc. | 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
CA2814011A1 (en) | 2010-10-11 | 2012-04-19 | Axikin Pharmaceuticals, Inc. | Salts of arylsulfonamide ccr3 antagonists |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
US20140079686A1 (en) | 2010-12-06 | 2014-03-20 | Shikha P. Barman | Methods For Treating Baldness And Promoting Hair Growth |
WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
WO2012106299A1 (en) | 2011-01-31 | 2012-08-09 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
AR085352A1 (es) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |
CN107375293A (zh) | 2011-03-11 | 2017-11-24 | 细胞基因公司 | 利用3‑(5‑氨基‑2‑甲基‑4‑氧‑4h‑喹唑啉‑3‑基)‑哌啶‑2,6‑二酮治疗癌症的方法 |
WO2012135175A1 (en) | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
SG193982A1 (en) | 2011-03-28 | 2013-11-29 | Mei Pharma Inc | (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases |
WO2012135166A1 (en) | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2012177962A1 (en) | 2011-06-23 | 2012-12-27 | Map Pharmaceuticals, Inc. | Novel fluoroergoline analogs |
TWI565709B (zh) | 2011-07-19 | 2017-01-11 | 英菲尼提製藥股份有限公司 | 雜環化合物及其用途 |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
US10154964B2 (en) | 2011-09-07 | 2018-12-18 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US9403863B2 (en) | 2011-09-12 | 2016-08-02 | Idenix Pharmaceuticals Llc | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
EP2755985B1 (en) | 2011-09-12 | 2017-11-01 | Idenix Pharmaceuticals LLC | Compounds and pharmaceutical compositions for the treatment of viral infections |
US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
TWI650321B (zh) | 2011-10-14 | 2019-02-11 | 美商安比特生物科學公司 | 雜環化合物及其使用方法 |
WO2013095707A1 (en) | 2011-12-19 | 2013-06-27 | Map Pharmaceuticals, Inc. | Novel iso-ergoline derivatives |
EP2793583A4 (en) | 2011-12-21 | 2015-08-12 | Map Pharmaceuticals Inc | NOVEL NEUROMODULATORY CONNECTIONS |
WO2013130600A1 (en) | 2012-02-29 | 2013-09-06 | Ambit Biosciences Corporation | Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith |
KR20140138293A (ko) | 2012-03-16 | 2014-12-03 | 액시킨 파마수티컬스 인코포레이티드 | 3,5-다이아미노피라졸 키나아제 억제제 |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
JP6165848B2 (ja) | 2012-05-22 | 2017-07-19 | イデニク ファーマシューティカルズ エルエルシー | 肝疾患のためのd−アミノ酸化合物 |
US9109001B2 (en) | 2012-05-22 | 2015-08-18 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphoramidate prodrugs for HCV infection |
US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
US9221788B2 (en) | 2012-08-09 | 2015-12-29 | Celgene Corporation | Salts and solid forms of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same |
KR102266509B1 (ko) | 2012-08-09 | 2021-06-16 | 셀진 코포레이션 | 면역-관련 및 염증성 질환의 치료 |
EP2890370B1 (en) | 2012-08-31 | 2019-10-09 | The Regents of the University of California | Agents useful for treating obesity, diabetes and related disorders |
KR20150053906A (ko) | 2012-09-07 | 2015-05-19 | 액시킨 파마수티컬스 인코포레이티드 | 동위원소 농축 아릴설폰아미드 ccr3 길항제 |
WO2014055647A1 (en) | 2012-10-03 | 2014-04-10 | Mei Pharma, Inc. | (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases |
AU2013329521B2 (en) | 2012-10-08 | 2018-04-19 | Centre National De La Recherche Scientifique | 2'-chloro nucleoside analogs for HCV infection |
WO2014063019A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
CN105102000B (zh) | 2012-11-01 | 2021-10-22 | 无限药品公司 | 使用pi3激酶亚型调节剂的癌症疗法 |
WO2014074765A2 (en) | 2012-11-08 | 2014-05-15 | Summa Health System | Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing |
EP2920195A1 (en) | 2012-11-14 | 2015-09-23 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
WO2014078436A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
DK2925718T3 (en) | 2012-11-30 | 2018-10-22 | Novomedix Llc | SUBSTITUTED BIARYL SULPHONAMIDS AND USE THEREOF |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
US8895743B2 (en) | 2012-12-21 | 2014-11-25 | Map Pharmaceuticals, Inc. | Methysergide derivatives |
WO2014110305A1 (en) | 2013-01-11 | 2014-07-17 | Mayo Foundation For Medical Education And Research | Vitamins c and k for treating polycystic diseases |
GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
EP2970194A1 (en) | 2013-03-15 | 2016-01-20 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
WO2014189933A1 (en) * | 2013-05-22 | 2014-11-27 | Empire Technology Development Llc | Long delayed release laxative |
EP3811974A1 (en) | 2013-05-30 | 2021-04-28 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
RU2016111675A (ru) | 2013-08-30 | 2017-10-04 | Эмбит Байосайенсиз Корпорейшн | Соединения биарилацетамида и способы их применения |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
US9700549B2 (en) | 2013-10-03 | 2017-07-11 | David Wise | Compositions and methods for treating pelvic pain and other conditions |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EA201690713A1 (ru) | 2013-10-04 | 2016-08-31 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
WO2015066370A1 (en) | 2013-11-01 | 2015-05-07 | Idenix Pharmaceuticals, Inc. | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
BR112016011949A8 (pt) | 2013-11-27 | 2020-04-28 | Idenix Pharmaceuticals Llc | composto, composição farmacêutica, e, uso dos mesmos |
US20170198005A1 (en) | 2013-11-27 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
US10683321B2 (en) | 2013-12-18 | 2020-06-16 | Idenix Pharmaceuticals Llc | 4′-or nucleosides for the treatment of HCV |
KR20160107254A (ko) | 2014-01-10 | 2016-09-13 | 존슨 앤드 존슨 컨수머 인코포레이티드 | 고주파 및 손실 코팅된 입자를 사용하여 정제를 제조하는 방법 |
WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
CA2943231C (en) | 2014-03-20 | 2023-10-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
PT3119762T (pt) | 2014-03-20 | 2021-08-31 | Capella Therapeutics Inc | Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro |
WO2015157559A2 (en) | 2014-04-09 | 2015-10-15 | Siteone Therapeutics, Inc. | 10',11'-modified saxitoxins for the treatment of pain |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
MX2016014731A (es) | 2014-05-12 | 2017-05-04 | Conatus Pharmaceuticals Inc | Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa. |
JP2017516779A (ja) | 2014-05-28 | 2017-06-22 | アイデニクス・ファーマシューティカルズ・エルエルシー | 癌治療のためのヌクレオシド誘導体 |
US9527815B2 (en) | 2014-06-18 | 2016-12-27 | Biotheryx, Inc. | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases |
ES2715500T3 (es) | 2014-06-19 | 2019-06-04 | Ariad Pharma Inc | Compuestos de heteroarilo para la inhibición de la quinasa |
US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
AU2015314830B2 (en) | 2014-09-12 | 2021-01-07 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
HUE051693T2 (hu) | 2014-10-21 | 2021-03-29 | Ariad Pharma Inc | 5-Klór-N4-[2-(dimetilfoszforil)-fenil]-N2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)-piperidin-1-il] -pirimidin-2,4-diamin kristályos formái |
EP3209658A1 (en) | 2014-10-24 | 2017-08-30 | Biogen MA Inc. | Diterpenoid derivatives and methods of use thereof |
EP3215127B1 (en) | 2014-11-07 | 2020-10-28 | Sublimity Therapeutics Limited | Compositions comprising cyclosporin |
MY191736A (en) | 2014-12-23 | 2022-07-13 | Axikin Pharmaceuticals Inc | 3,5-diaminopyrazole kinase inhibitors |
CN107428745A (zh) | 2015-01-20 | 2017-12-01 | Xoc制药股份有限公司 | 麦角灵化合物及其用途 |
CA2974113A1 (en) | 2015-01-20 | 2016-07-28 | Xoc Pharmaceuticals, Inc. | Isoergoline compounds and uses thereof |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US10815264B2 (en) | 2015-05-27 | 2020-10-27 | Southern Research Institute | Nucleotides for the treatment of cancer |
MX2017017015A (es) | 2015-06-23 | 2018-02-26 | Neurocrine Biosciences Inc | Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos. |
EP3385395B9 (en) | 2015-08-17 | 2020-05-20 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyl transferase inhibitors |
US10112953B2 (en) | 2015-09-30 | 2018-10-30 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
KR20180075591A (ko) | 2015-10-30 | 2018-07-04 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 발베나진 염 및 그의 다형체 |
WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
HUE059065T2 (hu) | 2015-12-23 | 2022-10-28 | Neurocrine Biosciences Inc | Szintetikus eljárás (S)-(2R,3R,11BR)-3-izobutil-9,10-dimetoxi-2,3,4,6,7,11B-hexahidro-1H-pirido [2,1-A]izokinolin-2-il-2-amino-3-metilbutanoát-di(4-metilbenzolszulfonát) elõállítására |
WO2017117478A1 (en) | 2015-12-31 | 2017-07-06 | Conatus Pharmaceuticals Inc. | Methods of using caspase inhibitors in treatment of liver disease |
CN113662941A (zh) | 2016-01-08 | 2021-11-19 | 细胞基因公司 | 抗增殖化合物以及其药物组合物和用途 |
WO2017120415A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
CA3010801A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
CN108884019A (zh) | 2016-04-11 | 2018-11-23 | 克雷西奥生物科技有限公司 | 氘代氯胺酮衍生物 |
WO2017180794A1 (en) | 2016-04-13 | 2017-10-19 | Skyline Antiinfectives, Inc. | Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams |
WO2017184968A1 (en) | 2016-04-22 | 2017-10-26 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
CN109476635B (zh) | 2016-04-29 | 2021-07-13 | Fgh生物科技公司 | 用于治疗疾病的二取代吡唑类化合物 |
TWI753910B (zh) | 2016-05-16 | 2022-02-01 | 美商拜歐斯瑞克斯公司 | 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途 |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
CA3036195A1 (en) | 2016-09-07 | 2018-03-15 | Fgh Biotech, Inc. | Di-substituted pyrazole compounds for the treatment of diseases |
KR20190058550A (ko) | 2016-09-19 | 2019-05-29 | 메이 파마, 아이엔씨. | 병용 요법 |
GR1009149B (el) * | 2016-10-25 | 2017-10-31 | Φαρματεν Αβεε | Φαρμακευτικα σκευασματα που περιλαμβανουν εναν εστερα φουμαρικου οξεως και μεθοδος παραγωγης αυτων |
WO2018085518A2 (en) | 2016-11-03 | 2018-05-11 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
US10988442B2 (en) | 2016-11-09 | 2021-04-27 | Novomedix, Llc | Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use |
US10106521B2 (en) | 2016-11-09 | 2018-10-23 | Phloronol, Inc. | Eckol derivatives, methods of synthesis and uses thereof |
WO2018102455A1 (en) | 2016-12-01 | 2018-06-07 | Ignyta, Inc. | Methods for the treatment of cancer |
JP2020500875A (ja) | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
CA3051832A1 (en) | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
US9956215B1 (en) | 2017-02-21 | 2018-05-01 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
AU2018225566B2 (en) | 2017-02-21 | 2019-11-07 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
US11555031B2 (en) | 2017-03-20 | 2023-01-17 | The Broad Institute, Inc. | Compounds and methods for regulating insulin secretion |
US11279706B2 (en) | 2017-03-29 | 2022-03-22 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
EP3601291A1 (en) | 2017-03-29 | 2020-02-05 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
US20200179352A1 (en) | 2017-04-26 | 2020-06-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
JOP20190219A1 (ar) | 2017-05-09 | 2019-09-22 | Cardix Therapeutics LLC | تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية |
US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
JP7237941B2 (ja) | 2017-05-19 | 2023-03-13 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置用の融合複素環式芳香族アニリン化合物 |
JP7212956B2 (ja) | 2017-05-19 | 2023-01-26 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置用のピロロピリジン-アニリン化合物 |
JP2020522504A (ja) | 2017-06-01 | 2020-07-30 | エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc | 多環式化合物およびそれらの用途 |
CA3071854A1 (en) | 2017-08-07 | 2019-02-14 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
US10806730B2 (en) | 2017-08-07 | 2020-10-20 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
TW201919622A (zh) | 2017-09-21 | 2019-06-01 | 美商紐羅克里生物科學有限公司 | 高劑量戊苯那嗪(valbenazine)調配物及組合物、方法以及相關套組 |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
EA202090932A1 (ru) | 2017-10-10 | 2021-05-20 | Нейрокрин Байосайенсиз, Инк | Способы введения некоторых vmat2-ингибиторов |
MX2020004546A (es) * | 2017-11-01 | 2020-10-05 | Edgemont Pharmaceuticals Llc Trust | Composiciones farmaceuticas orales de lorazepam resistentes al alcohol. |
WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
WO2019139871A1 (en) | 2018-01-10 | 2019-07-18 | Cura Therapeutics Llc | Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications |
TWI823890B (zh) | 2018-01-10 | 2023-12-01 | 美商克拉治療有限責任公司 | 包含苯基磺醯胺之醫藥組合物及其治療應用 |
SG11202011544UA (en) | 2018-06-14 | 2020-12-30 | Neurocrine Biosciences Inc | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
US11447497B2 (en) | 2018-06-29 | 2022-09-20 | Histogen, Inc. | (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases |
JOP20200336A1 (ar) | 2018-08-15 | 2020-12-22 | Neurocrine Biosciences Inc | طرق إعطاء مثبطات vmat2 معينة |
EP3860714B1 (en) | 2018-10-03 | 2023-09-06 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
CN113286591A (zh) | 2018-11-01 | 2021-08-20 | 库拉肿瘤学公司 | 用法尼基转移酶抑制剂治疗癌症的方法 |
WO2020106303A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers |
US20230013227A1 (en) | 2018-11-20 | 2023-01-19 | Nflection Therapeutics, Inc. | Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks |
CA3120371A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
WO2020106308A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
WO2020132071A1 (en) | 2018-12-19 | 2020-06-25 | Shy Therapeutics. Llc | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease |
CN113365630A (zh) | 2018-12-21 | 2021-09-07 | 库拉肿瘤学公司 | 用于鳞状细胞癌的疗法 |
WO2020132700A1 (en) | 2018-12-21 | 2020-06-25 | Fgh Biotech Inc. | Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof |
US11447468B2 (en) | 2019-02-06 | 2022-09-20 | Dice Alpha, Inc. | IL-17 ligands and uses thereof |
WO2020180663A1 (en) | 2019-03-01 | 2020-09-10 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
TW202100506A (zh) | 2019-03-07 | 2021-01-01 | 美商柯納特斯製藥公司 | 半胱天冬酶(caspase)抑制劑及其使用方法 |
US20220143006A1 (en) | 2019-03-15 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
EP3946338A1 (en) | 2019-03-29 | 2022-02-09 | Kura Oncology, Inc. | Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors |
US20220168296A1 (en) | 2019-04-01 | 2022-06-02 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
US20220305001A1 (en) | 2019-05-02 | 2022-09-29 | Kura Oncology, Inc. | Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors |
AU2020310190A1 (en) | 2019-07-11 | 2022-02-24 | Cura Therapeutics, Llc | Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications |
US20220274922A1 (en) | 2019-07-11 | 2022-09-01 | Cura Therapeutics, Llc | Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications |
CA3143294A1 (en) | 2019-07-26 | 2021-02-04 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease |
US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
WO2021055376A1 (en) | 2019-09-16 | 2021-03-25 | Dice Alpha, Inc. | Il-17a modulators and uses thereof |
WO2021059023A1 (en) | 2019-09-26 | 2021-04-01 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
AU2020359526A1 (en) | 2019-10-01 | 2022-04-21 | Molecular Skin Therapeutics, Inc. | Benzoxazinone compounds as KLK5/7 dual inhibitors |
US11529331B2 (en) | 2020-05-29 | 2022-12-20 | Boulder Bioscience Llc | Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane |
US20230227466A1 (en) | 2020-06-18 | 2023-07-20 | Shy Therapeutics, Llc | Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
MX2023001741A (es) | 2020-08-14 | 2023-04-25 | Siteone Therapeutics Inc | Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor. |
WO2022164997A1 (en) | 2021-01-27 | 2022-08-04 | Shy Therapeutics, Llc | Methods for the treatment of fibrotic disease |
WO2022165000A1 (en) | 2021-01-27 | 2022-08-04 | Shy Therapeutics, Llc | Methods for the treatment of fibrotic disease |
WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
JP2024510196A (ja) | 2021-03-10 | 2024-03-06 | ダイス・モレキュールズ・エスブイ・インコーポレイテッド | アルファvベータ6およびアルファvベータ1インテグリン阻害剤およびその使用 |
EP4326721A1 (en) | 2021-04-22 | 2024-02-28 | Protego Biopharma, Inc. | Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis |
IT202100013697A1 (it) * | 2021-05-26 | 2022-11-26 | Prosol S P A | Lievito vivo rivestito e procedimento per la sua produzione |
WO2022251533A1 (en) | 2021-05-27 | 2022-12-01 | Protego Biopharma, Inc. | Heteroaryl diamide ire1/xbp1s activators |
EP4176724A1 (en) | 2021-11-09 | 2023-05-10 | Universität Hohenheim | Use of an oleogel as a layer or coating |
WO2023102378A1 (en) | 2021-11-30 | 2023-06-08 | Kura Oncology, Inc. | Macrocyclic compounds having farnesyltransferase inhibitory activity |
US11932665B2 (en) | 2022-01-03 | 2024-03-19 | Lilac Therapeutics, Inc. | Cyclic thiol prodrugs |
US11981694B2 (en) | 2022-01-03 | 2024-05-14 | Lilac Therapeutics, Inc. | Acyclic thiol prodrugs |
TW202400593A (zh) | 2022-03-28 | 2024-01-01 | 美商艾索司特瑞克斯公司 | Myst家族離胺酸乙醯轉移酶之抑制劑 |
WO2023192904A1 (en) | 2022-03-30 | 2023-10-05 | Biomarin Pharmaceutical Inc. | Dystrophin exon skipping oligonucleotides |
GB2619907A (en) | 2022-04-01 | 2023-12-27 | Kanna Health Ltd | Novel crystalline salt forms of mesembrine |
US20230331693A1 (en) | 2022-04-14 | 2023-10-19 | Bristol-Myers Squibb Company | Gspt1 compounds and methods of use of the novel compounds |
WO2023201348A1 (en) | 2022-04-15 | 2023-10-19 | Celgene Corporation | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
WO2023215781A1 (en) | 2022-05-05 | 2023-11-09 | Biomarin Pharmaceutical Inc. | Method of treating duchenne muscular dystrophy |
US20240158370A1 (en) | 2022-09-09 | 2024-05-16 | Innovo Therapeutics, Inc. | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS |
US20240131005A1 (en) | 2022-09-30 | 2024-04-25 | Boulder Bioscience Llc | Compositions and methods for treating non-hemorrhagic closed head injury |
WO2024086246A2 (en) | 2022-10-18 | 2024-04-25 | Eluciderm Inc. | 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment |
US20240174695A1 (en) | 2022-10-26 | 2024-05-30 | Protego Biopharma, Inc. | Spirocycle Containing Bicyclic Heteroaryl Compounds |
US20240174673A1 (en) | 2022-10-26 | 2024-05-30 | Protego Biopharma, Inc. | Spirocycle Containing Pyridine Compounds |
US20240174672A1 (en) | 2022-10-26 | 2024-05-30 | Protego Biopharma, Inc. | Spirocycle Containing Pyridone Compounds |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3131123A (en) * | 1959-03-13 | 1964-04-28 | Lab Francais De Therapeutique | Enteric tablets and manufacture thereof |
DE2057853B2 (de) * | 1970-11-25 | 1974-02-28 | Roehm Gmbh, 6100 Darmstadt | Verfahren zur Herstellung von Arzneimittelkugelchen |
US4035899A (en) * | 1975-03-10 | 1977-07-19 | Olympus Optical Co., Ltd. | Automatic tape cassette-assembling system |
JPS52151717A (en) * | 1976-06-09 | 1977-12-16 | Shionogi & Co Ltd | Sugar coating on solid preparations |
FR2471186A1 (fr) * | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
JPS57171428A (en) * | 1981-04-13 | 1982-10-22 | Sankyo Co Ltd | Preparation of coated solid preparation |
US4851231A (en) * | 1982-12-13 | 1989-07-25 | Alza Corporation | System for delivering drug in selected environment of use |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
DK62184D0 (da) * | 1984-02-10 | 1984-02-10 | Benzon As Alfred | Diffusionsovertrukket polydepotpraeparat |
US4729893A (en) | 1984-12-26 | 1988-03-08 | Robert L. Letcher | Enteric encapsulation of ancrod for oral administration |
US4777089A (en) | 1985-05-08 | 1988-10-11 | Lion Corporation | Microcapsule containing hydrous composition |
US4683092A (en) | 1985-07-03 | 1987-07-28 | Damon Biotech, Inc. | Capsule loading technique |
GB8518301D0 (en) * | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
US4853249A (en) * | 1985-11-15 | 1989-08-01 | Taisho Pharmaceutical Co., Ltd. | Method of preparing sustained-release pharmaceutical/preparation |
IL77186A0 (en) * | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
US5089269A (en) | 1987-11-07 | 1992-02-18 | Shiseido Company Ltd. | Cosmetic containing fine soft microcapsules |
JPS62195323A (ja) * | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | 胃内滞留型粒子 |
IT1204294B (it) * | 1986-03-11 | 1989-03-01 | Gentili Ist Spa | Metodo di fabbricazione di granulari atti a produzione di compresse rivestite,per uso orale,a rilascio controllato |
US5238686A (en) * | 1986-03-27 | 1993-08-24 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
IE58401B1 (en) * | 1986-06-20 | 1993-09-08 | Elan Corp Plc | Controlled absorption pharmaceutical composition |
GB8628359D0 (en) * | 1986-11-27 | 1986-12-31 | Zyma Sa | Galenical formulation |
SE460945B (sv) * | 1987-01-15 | 1989-12-11 | Lejus Medical Ab | En multipel-unit-dos komposition av furosemid |
CH668553A5 (de) | 1987-02-02 | 1989-01-13 | Mepha Ag | Arzneimittel mit verzoegerter wirkstofffreisetzung. |
GB8702411D0 (en) * | 1987-02-03 | 1987-03-11 | Zyma Sa | Swellable pellets |
US4857335A (en) | 1987-03-27 | 1989-08-15 | Lim Technology Laboratories, Inc. | Liquid controlled release formulations and method of producing same via multiple emulsion process |
US4891223A (en) * | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
US4923645A (en) | 1987-11-16 | 1990-05-08 | Damon Biotech, Inc. | Sustained release of encapsulated molecules |
US4971805A (en) * | 1987-12-23 | 1990-11-20 | Teysan Pharmaceuticals Co., Ltd. | Slow-releasing granules and long acting mixed granules comprising the same |
JPH0768125B2 (ja) | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
US4857337A (en) * | 1988-05-24 | 1989-08-15 | American Home Products Corp. (Del) | Enteric coated aspirin tablets |
US4917892A (en) | 1988-06-28 | 1990-04-17 | Temple University | Encapsulated topical delivery system |
US5296236A (en) | 1988-09-16 | 1994-03-22 | Recordati S.A., Chemical And Pharmaceutical Company | Controlled release therapeutic system for a liquid pharmaceutical formulations |
IT1230576B (it) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5084278A (en) * | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
PH27186A (en) * | 1989-09-07 | 1993-04-16 | Ciba Geigy Ag | Double-coated granules of disodium pamidronate |
US5527545A (en) | 1989-09-18 | 1996-06-18 | Recordati S.A. Chemical And Pharmaceutical Company | Liquid-suspension controlled-release pharmaceutical composition |
GB8926639D0 (en) * | 1989-11-24 | 1990-01-17 | Agricultural & Food Res | Delayed release formulations |
IE66933B1 (en) | 1990-01-15 | 1996-02-07 | Elan Corp Plc | Controlled absorption naproxen formulation for once-daily administration |
US5198227A (en) * | 1990-01-22 | 1993-03-30 | Mcneil-Ppc, Inc. | Dual subcoated simulated capsule medicament |
IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
US5175003A (en) * | 1990-04-06 | 1992-12-29 | Biosytes Usa, Inc. | Dual mechanism controlled release system for drug dosage forms |
IT1246382B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
JP2773959B2 (ja) * | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
US5316772A (en) * | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
DE69132166T2 (de) | 1990-12-20 | 2000-12-21 | Warner Jenkinson Co Inc | Filmbildende zusammensetzungen aus feuchtem pulver |
US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
CA2107678A1 (en) | 1991-04-08 | 1992-10-09 | Kouichi Nakamichi | Capsule |
JP3313124B2 (ja) | 1991-07-31 | 2002-08-12 | 森下仁丹株式会社 | 親水性物質を内容物とするシームレスカプセルおよびその製法 |
US5273760A (en) * | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
IT1260505B (it) * | 1992-06-01 | 1996-04-09 | Poli Ind Chimica Spa | Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon |
US5262172A (en) * | 1992-06-19 | 1993-11-16 | Digestive Care Inc. | Compositions of gastric acid-resistant microspheres containing buffered bile acids |
US5302400A (en) * | 1992-06-22 | 1994-04-12 | Digestive Care Inc. | Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids |
US5330759A (en) * | 1992-08-26 | 1994-07-19 | Sterling Winthrop Inc. | Enteric coated soft capsules and method of preparation thereof |
US5654004A (en) | 1992-11-06 | 1997-08-05 | Hisamitsu Pharmaceutical Co., Inc. | Oral pharmaceutical preparation releasable in the lower digestive tract |
SE9301057L (sv) | 1993-03-30 | 1994-10-01 | Pharmacia Ab | Beredning med kontrollerad frisättning |
JPH072650A (ja) * | 1993-06-18 | 1995-01-06 | Tanabe Seiyaku Co Ltd | 放出部位制御型製剤 |
US5396626A (en) * | 1993-08-04 | 1995-03-07 | Taligent, Inc. | Object-oriented locator system |
JPH07223970A (ja) * | 1994-02-10 | 1995-08-22 | Tanabe Seiyaku Co Ltd | 消化管内適所放出製剤 |
US5482718A (en) * | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
US5464633A (en) * | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
US5536507A (en) * | 1994-06-24 | 1996-07-16 | Bristol-Myers Squibb Company | Colonic drug delivery system |
-
1997
- 1997-01-29 US US08/790,530 patent/US5891474A/en not_active Expired - Lifetime
- 1997-12-16 AU AU56755/98A patent/AU5675598A/en not_active Abandoned
- 1997-12-16 PT PT97953009T patent/PT954293E/pt unknown
- 1997-12-16 ES ES97953009T patent/ES2232886T3/es not_active Expired - Lifetime
- 1997-12-16 DE DE69731847T patent/DE69731847T2/de not_active Expired - Lifetime
- 1997-12-16 EP EP97953009A patent/EP0954293B1/en not_active Expired - Lifetime
- 1997-12-16 US US08/991,814 patent/US6190692B1/en not_active Expired - Fee Related
- 1997-12-16 JP JP53177098A patent/JP4053604B2/ja not_active Expired - Fee Related
- 1997-12-16 WO PCT/IB1997/001646 patent/WO1998032426A1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007505921A (ja) * | 2003-09-19 | 2007-03-15 | ペンウェスト ファーマシューティカルズ カンパニー | 遅延放出剤形 |
Also Published As
Publication number | Publication date |
---|---|
AU5675598A (en) | 1998-08-18 |
US6190692B1 (en) | 2001-02-20 |
DE69731847D1 (de) | 2005-01-05 |
WO1998032426A1 (en) | 1998-07-30 |
ES2232886T3 (es) | 2005-06-01 |
EP0954293B1 (en) | 2004-12-01 |
EP0954293A1 (en) | 1999-11-10 |
US5891474A (en) | 1999-04-06 |
JP4053604B2 (ja) | 2008-02-27 |
DE69731847T2 (de) | 2006-08-03 |
PT954293E (pt) | 2005-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001509157A (ja) | 時間特異的放出制御型投与製剤及びその製法 | |
RU2385712C2 (ru) | Рецептура с контролируемым высвобождением | |
KR101158968B1 (ko) | 친수성/친유성 중합체 매트릭스 용량적 제제 | |
JP2720932B2 (ja) | 経口投与用アセトアミノフエン錠剤の製造法及びアセトアミノフエン二層錠剤 | |
EP0948320B1 (en) | PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN | |
AU2012250862B2 (en) | Rapid dissolve tablet compositions for vaginal administration | |
JP2538191B2 (ja) | 投与用製剤原料組成物 | |
CN1384740A (zh) | 含有曲马朵糖精盐的持续释放给药剂型 | |
JPS61501151A (ja) | 拡散被覆された複合単位服用剤 | |
JPH10502390A (ja) | 医薬品用の徐放性マトリックス | |
JP2001500879A (ja) | 可溶性に乏しい薬物および不溶性の物質の制御放出のための胃滞留性経口薬物投薬形態 | |
JPH09502738A (ja) | 制御放出のための新規ビーズおよびそれらを含有する医薬製剤 | |
JP2003503341A (ja) | 少なくとも一つの適時パルスを生ずる制御された放出用の医薬投与形態 | |
JPS635020A (ja) | 制御放出性イブプロフエン製剤 | |
TWI282737B (en) | Sustained release oral preparations | |
KR102173549B1 (ko) | 복합 생약재 추출물 함유 방출 조절 제제 | |
WO2008102235A1 (en) | Controlled release formulations of alfuzosin | |
EP1436009A1 (en) | Pharmaceutical formulation | |
Sampath | Formulation and Evaluation of Quetiapine Fumarate Loaded Carbopol 974p Mucoadhesive Microspheres for the Treatment of Schizophrenia | |
ZA200209226B (en) | Hydrophilic/lipophilic polymeric matrix dosage formulation. | |
KR19980077329A (ko) | 이중층 약물 함유 제어방출성 제제 | |
AU2002341496A1 (en) | Pharmaceutical formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060725 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061024 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061211 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070313 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070531 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070713 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070712 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070827 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070913 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071206 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101214 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101214 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111214 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121214 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131214 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |